|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.52 CHF | -0.39% |
|
-1.30% | -0.41% |
| 12:33am | US FDA mandates label updates on CAR-T cancer therapies | RE |
| Apr. 18 | NOVARTIS AG : UBS reiterates its Buy rating | ZD |
ZURICH (Reuters) - Novartis has secured the U.S. Food and Drug Administration's Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.
Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a form of the disease for which there are no targeted therapies now, the Basel-based company said on Friday.
(This story fixes typographical error in first paragraph.)
(Reporting by John Miller; Editing by Michael Shields and David Goodman)
| 1st Jan change | Capi. | |
|---|---|---|
| -0.41% | 203B | |
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.96% | 211B | |
| -10.02% | 194B | |
| -11.81% | 144B | |
| -8.80% | 141B |
NOVARTIS AG 
